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ARTICLE
Powerful Multilocus Tests of Genetic Association in the Presence
of Gene-Gene and Gene-Environment Interactions
Nilanjan Chatterjee, Zeynep Kalaylioglu, Roxana Moslehi, Ulrike Peters, and Sholom Wacholder
In modern genetic epidemiology studies, the association between the disease and a genomic region, such as a candidate
gene, is often investigated using multiple SNPs. We propose a multilocus test of genetic association that can account for
genetic effects that might be modiﬁed by variants in other genes or by environmental factors. We consider use of the
venerable and parsimonious Tukey’s 1–degree-of-freedom model of interaction, which is natural when individual SNPs
within a gene are associated with disease through a common biological mechanism; in contrast, many standard regression
models are designed as if each SNP has unique functional signiﬁcance. On the basis of Tukey’s model, we propose a
novel but computationally simple generalized test of association that can simultaneously capture both the main effects
of the variants within a genomic region and their interactions with the variants in another region or with an environ-
mental exposure. We compared performance of our method with that of two standard tests of association, one ignoring
gene-gene/gene-environment interactions and the other based on a saturated model of interactions. We demonstrate
major power advantages of our method both in analysis of data from a case-control study of the association between
colorectal adenoma and DNA variants in the NAT2 genomic region, which are well known to be related to a common
biological phenotype, and under different models of gene-gene interactions with use of simulated data.
From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD (N.C.; R.M.; S.W.); InformationManagement System,
Rockville, MD (Z.K.); and Fred Hutchinson Cancer Research Center, Seattle (U.P.)
Received July 17, 2006; accepted for publication September 22, 2006; electronically published October 20, 2006.
Address for correspondence and reprints: Dr. Nilanjan Chatterjee, 6120 Executive Boulevard, EPS 8038, Rockville, MD 20852. E-mail: chattern
@mail.nih.gov
Am. J. Hum. Genet. 2006;79:1002–1016.  2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7906-0003$15.00
The identiﬁcation of a large number of SNPs across the
human genome has created great opportunity for ﬁne
mapping disease susceptibility loci (DSL) through popu-
lation-based association studies.1–5 An increasingly popu-
lar design of association studies has been the indirect ap-
proach, in which the association between the disease and
a genomic region, such as a candidate gene, is studied
using a set of marker SNPs that themselves may or may
not have causal effects but would be likely to be in linkage
disequilibrium (LD) with the underlying causal variants,
if any exist. The availability of LD information across the
human genome from the International HapMap project6,7
and a number of other emerging databases8,9 is now en-
abling researchers to select informative sets of tagging
SNPs that could be used as markers in indirect association
studies.10–13
A central statistical issue for indirect association studies
is how to optimally analyze the association of a disease
phenotype with multiple tightly linked SNPs within a ge-
nomic region. A locus-by-locus approach could be optimal
if one of the genotyped SNPs itself is causal. In contrast,
multilocus tests that assess the association of a disease with
multiple marker SNPs simultaneously could be superior
when several SNPs may be associated with the disease be-
cause of either their direct causal effects or their LD with
the underlying causal variant(s) in the region. Two classes
of multivariate tests, one based on multilocus genotype
data12,14 and the other based on reconstructed haplotype
information,15,16 are now popularly used in practice.
Another important issue for identiﬁcation of DSL in com-
plex diseases is that the etiologic effects of the underlying
causal variants are likely to be complex because of a num-
ber of factors, including but not limited to gene-gene and
gene-environment interactions. It has been long recog-
nized that failing to account for these sources of hetero-
geneity could dramatically reduce the power of detecting
DSLs in both linkage and association studies. Since the
late 1980s, a variety of multipoint methods have been
developed to account for gene-gene interaction in linkage
analysis.17–21 Methods for linkage scans accounting for
gene-environment interactions have also received some
attention.22,23 More recently, a number of powerful meth-
ods also have been developed for incorporating gene-gene
interactions in association studies.24,25 These methods,
however, are mostly suitable for direct association studies
involving candidate SNPs and cannot exploit the structure
of indirect association studies involving groups of tightly
linked SNPs that could be statistically correlated because
of LD or functionally related because of underlying com-
mon biological mechanisms.
In this article, we propose a novel method for incorpo-
rating gene-gene and gene-environment interactions into
association studies. When several SNPs are involved within
a gene, the number of parameters required in standard
statistical models of gene-gene and gene-environment in-
teractions could easily become very large, potentially caus-
ing loss of power due to either the use of increased dfs or
the need for multiple-testing adjustments. We consider
use of Tukey’s 1-df model of interaction.26,27 We show that
this parsimonious form of interaction can be motivated
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Table 1. Haplotype Frequencies Used for
Simulating Genotype Data on Marker SNPs
for Two Candidate Genes
Haplotype Frequency
:G1
000000 .3211
001101 .1204
010000 .0909
000001 .0785
111001 .0722
110001 .0708
000010 .0610
011001 .0523
110000 .0468
100000 .0353
001000 .0279
010001 .0228
:G2
100010 .3506
010001 .2819
010100 .1274
100000 .0678
000000 .0407
101100 .0401
000010 .0307
010010 .0237
010000 .0226
100001 .0144
Figure 1. A conceptual framework for modeling gene-gene in-
teractions in indirect-association studies.
Table 2. Approximate Relative-Risk Models Used for Simulating Disease End
Points, Given the Genotypes for Two Causal Loci in Candidate Genes andG G1 2
Model
No. of Alleles
( ,∗S p 01
)a∗S p 02
( ,S  11
)S p 02
( ,S p 01
)S  12
( ,S  11
)S  12
General form 1 exp (v )1 exp (v )2 exp (v  v  v )1 2 12
Purely epistatic 1 1 1 f
Multiplicative 1 f f 2f
Additive 1 f1 f2 f  f  11 2
Crossover 1 f1 (!1) 1 f12 (11)
a and refer to the number of copies of the variant allele in the causal loci of and ,∗ ∗S S G G1 2 1 2
respectively.
through a conceptual framework in which the observed
SNPs within a gene affect the risk of the disease through
an underlying common causal mechanism. Modern as-
sociation studies in which tagging SNPs are selected as
potential surrogates for underlying causal variants ﬁt into
this framework. Other examples where the framework is
very natural are also discussed.
We propose a novel multilocus test of genetic associa-
tion, based on Tukey’s model, that can efﬁciently exploit
the LD pattern among SNPs within a gene and can simul-
taneously account for their interactions with SNPs in an-
other gene or with an environmental exposure. We sim-
ulate case-control data, in a way that mimics modern as-
sociation study designs, to evaluate type I errors and pow-
ers of the proposed testing strategy. We also apply the
proposed methodology to a case-control study designed
to investigate the association between colorectal adenoma
and DNA variants in N-acetyltransferase 2 (NAT2 [MIM
243400]), a candidate gene that plays an important role
in detoxiﬁcation of aromatic amine carcinogens present
in cigarette smoke. Both the simulated and real data ex-
amples demonstrate major power advantages for the pro-
posed methodology over two alternative tests of associa-
tion, one ignoring interactions and the other incorporat-
ing a saturated model of interactions.
Material and Methods
A Latent-Variable Model and Tukey’s 1-df Form of
Interaction
Suppose that and are two candidate genes of interest forG G1 2
which and marker SNPs, respectively, have been genotyped.K K1 2
Let and denote the ge-S p (S ,S ,… ,S ) S p (S ,S ,… ,S )1 11 21 K 1 2 12 22 K 21 2
notype data for the corresponding sets of markers. In this article,
we assume that each marker genotype is recorded as “0,” “1,”Sij
or “2,” counting the number of copies of the minor or variant
allele. Figure 1 shows a schematic diagram for a hypothesized
model describing the relationship between the marker SNPs and
the disease through an underlying causal mechanism. Themodel
assumes that, for each gene , themarker data act as a surrogateG Si i
for an underlying biological phenotype, , that is causally relatedZi
to the disease. The associations between the markers and the
biological phenotypes for the two genes are described by two
separate linear models (ﬁg. 1, upper two boxes), where the error
terms and are assumed to be mean zero independent randome e1 2
variables. The risk of the disease, given the causal variables Z1
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Table 3. Empirical Signiﬁcance Level for Test of
Association with Region G1
,a ,b and Method2R fgeno 2
Relative Risk for Causal SNP in ( )G v2 2
1.0 2.0
90%:
.04:
Permutation .008 .012
Asymptotic .008 .011
.13:
Permutation .013 .011
Asymptotic .012 .009
75%:
.04:
Permutation .010 .009
Asymptotic .009 .008
.13:
Permutation .009 .004
Asymptotic .009 .004
60%:
.04:
Permutation .011 .012
Asymptotic .012 .012
.13:
Permutation .009 .009
Asymptotic .009 .008
a Multiple between genotypes and causal and marker loci.2R
b Allele frequency for causal SNP in .G2
and , is speciﬁed by a standard logistic model that involvesZ2
both main and interaction effects (ﬁg. 1, lower box). It is also
implicitly assumed that, given the true biological exposures Z1
and , the risk of the disease does not depend on the markersZ2
and .S S1 2
Before one proceeds further, it is useful to understand what the
latent variables and may be in practice. If the gene con-Z Z G1 2 i
tains a single causal locus , the variable could represent theL Zi i
genotype data for itself. If, for example, one of the selectedLi
markers is the causal locus and denotes the count for the cor-Zi
responding variant allele, then the assumed linear model describ-
ing the relationship between and would ﬁt perfectly—thatZ Si i
is, the error term would vanish, by the setting of for thee g p 1i ik
causal locus and for all the other markers. If the causalg p 0ik
locus is not selected as a marker, then the error term will not
generally disappear, but the magnitude of it could be expected
to be small for modern association studies that aim to select the
markers to be a panel of tagging SNPs that would have a very
high degree of LD, as measured by the criterion, with all the2R
genetic variations of the regions, including any possible causal
ones. The validity of the proposed framework, however, does not
depend on the existence of a single causal locus in each gene.
The variable could, for example, represent a quantitative bio-Zi
logical phenotype that may be governed by several different var-
iants within the same gene . In the study of colorectal adenomaGi
(see the “Results” section), the underlying biological phenotype
for the gene of interest, NAT2, is the N-acetyltransferase enzy-
matic activity level, which has been shown to be determined by
several single–base-pair substitutions in the gene and the asso-
ciated haplotypes/diplotypes.28,29
The logistic model shown in ﬁgure 1 (lower box) cannot be
used directly for association testing because, typically, the vari-
ables and are not observable. However, in this model, ex-Z Z1 2
pressing and in terms of and with use of the corre-Z Z S S1 2 1 2
sponding linear-regression models and assuming small variances
for the error terms and , a risk model for the disease (D), ine e1 2
terms of the observable SNPs, can be derived approximately in
the formula
K K1 2
log it[Pr (D p 1FS ,S )] p a b S  b S 1 2 k 1 k 1 k 1 k 21 1 2 2
k p1 k p11 2
K K1 2
v b b S S (1)  k 1 k 1 k 1 k 21 2 1 2
k p1 k p11 2
(see appendix A for details). We observe that equation (1) resem-
bles a traditional logistic-regression model, except that the SNPs
across two genes have the parsimonious Tukey’s 1-df form of
interaction.26,27 Thus, postulating the biological effect of the ob-
served SNPs to be determined by a smaller set of casual variables
leads to a very parsimonious model for gene-gene interactions.
The motivation of Tukey’s 1-df model for interaction through
the above latent-variable framework also allows extension of the
model in a number of different ways. For example, if some of the
SNPs within a gene are known a priori to have functional sig-
niﬁcance, then it may be desirable to capture possible interactions
between these functional SNPs of the same gene. Suppose andS11
are two such SNPs for gene . Then, the regression model forS G21 1
could be extended to allow for interaction between andZ S1 11
, asS21
K1
Z p m  g S  g S S  e . (2)1 1 k 1 k 1 (12)1 11 21 11 1
kp1
With the assumption that the models for andZ Pr (D p2
remain the same as before, the model for the risk of the1FZ ,Z )1 2
disease, in terms of the SNP data and , can now be derivedS S1 2
in the formula
K1
log it[Pr (D p 1FS ,S )]p a b S1 2 k 1 k 11 1
k p11
K2
 b S  b S S k 2 k 2 (12)1 11 212 2
k p12
K K1 2
v b b S S  k 1 k 2 k 1 k 21 2 1 2
k p1 k p11 2
K2
t b b S S S , (12)1 k 2 11 21 k 22 2
k p12
which includes both second- and third-order interactions. One
could also account for SNP-SNP interactions within a gene by
specifying the disease risk in terms of haplotypes instead of locus-
speciﬁc genotypes.
The proposed modeling framework can be easily extended to
incorporate gene-environment interactions. Suppose that the ge-
nomic region (e.g., NAT2) is believed to involve a biologicalG1
pathway through which an environmental variableX (e.g., smok-
ing) may act on the risk of a disease (e.g., colorectal adenoma).
Again, on the basis of the latent-variable approach, a model for
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Figure 2. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.01 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the purely epistatic model (see table 2). and∗S G G f1 1 2 1
denote minor-allele frequencies for causal SNPs in and , respectively, and denotes the value of multiple between the2 2f G G R R2 1 2 geno
causal and marker loci within a gene.
the disease risk in terms of the marker-SNPs and the environ-S1
mental variable X can be derived in the form
K P1
log it[Pr (D p 1FS ,X)] p a b S  g X 1 k 1 k 1 p p1 1
k p1 pp11
P K1
v b g S X ,  k 1 p k 1 p1 1
pp1 k p11
where { , , } is a set of suitably chosen design variables,X X …X1 2 P
such as dummy variables for categorical exposures, for represent-
ing the effects of the exposure X.
Association Testing
In this section, we study methods for hypothesis testing based
on the proposed model. When data on multiple putative risk
factors, such as multiple candidate genes, are available, one could
test a number of different types of hypotheses regarding the role
of these factors in the risk of the disease. For association studies,
the primary goal is to establish which of the factors, if any, are
related to the risk of the disease. If multiple factors are found to
be related to the disease, then a secondary hypothesis of interest
could be generated to test for speciﬁc forms of interaction among
the established risk factors. It is important, however, to realize
that, although the test of interaction itself may be of only sec-
ondary interest, accounting for heterogeneity of genetic effects
due to interactions can be vital for enhancing the power of the
primary hypothesis of association testing.
In the following sections, we develop an association-testing
framework involving two candidate genes, and . The sameG G1 2
framework can also be used to develop tests of associations in-
volving a candidate gene and an environmental exposure. We
assume a population-based case-control design of unrelated sub-
jects. All of the methods, however, are easily extendable to al-
ternative study designs, including family-based case-control and
case-parent–trio designs. For possible strategies for using the
methodology in general association studies that involve numer-
ous candidate genes, see the “Discussion” section.
The general principle.—We focus on the test of association for
; the methods for are symmetric. In model (1), the nullG G1 2
hypothesis of no association of disease with can be statisticallyG1
stated as
(1)H :b p 0, for all k p 1,…K ,0 k 1 1 11
which implies conditional independence of D and , given .G G1 2
The parameter not only appears in the model as the mainbk 11
effect for the marker but also contributes to all interactionS Kk 1 21
terms that could be deﬁned involving and the SNPs inS Kk 1 21
. Thus, it is best to describe , as a set of “gen-G b k p 1,…,K2 k 1 1 11
eralized association parameters” instead of as traditional “main”
or “interaction” effects.
A complication of association testing in model (1) is that, un-
der the null hypothesis of , the parameter v disappears from(1)H0
the model and, hence, is not estimable from the data. Thus, stan-
dard statistical tests, such as score- or likelihood-ratio tests, which
require estimation of all nuisance parameters of the model under
the null hypothesis, are not applicable. However, for each ﬁxed
value of v, irrespective of whether or not it is the true value for
the population, model (1) gives a valid way of testing the null
hypothesis . In particular, for each ﬁxed value of v, the likeli-(1)H0
hood score function for the parameter vector b p (b ,… ,b )1 11 K 11
can be shown to have zero expectation under the null hypothesis
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Figure 3. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.01 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the purely multiplicative model, with∗S G G f p f1 1 2 1 2
(see table 2). and denote minor-allele frequencies for causal SNPs in and , respectively, and denotes the value of multiple2f f G G R1 2 1 2 geno
between the causal and marker loci within a gene.2R
of . Thus, for each ﬁxed value of v, an unbiased score statistic(1)H0
could be formed for testing . Varying the value of v, one can(1)H0
get a family of score statistics. We propose to use the maximum
value of such score statistics over a suitable range of v as the ﬁnal
test statistics to be used.
Steps for deriving the test statistics.—We assume that cases andN1
controls have been sampled in the study and that, for eachN0
subject, i, the SNP-genotype vectors and have been recorded.S Sli 2i
In the following list, we describe the four major steps for deriving
the test statistics associated with . The test statistics for couldG G1 2
be derived by symmetry.
1. Obtain maximum-likelihood estimate a and b p (b ,… ,2 12
under the local null hypothesis . Under , the model(1) (1)b ) H HK 2 0 02
(1) becomes equivalent to a standard logistic-regressionmodel
involving the main effects of the SNPs in . Thus, a standardG2
logistic software package can be used to obtain . Letˆ ˆˆw p (a,b )2
denote evaluated atˆP (S ) Pr (D p 1FS ,S ) p Pr (D p 1FS )(1)H 2 1 2 20
and .ˆb p 0 w p w1
2. For a ﬁxed value of v, evaluate the score functions for the
parameters and at and , usingˆb k p 1,…,K b p 0 w p wk 1 1 1 11
the formula
N N K0 1 2
ˆ ˆS (v) p 1 v S b S [D  P (S )] , (3)(1) (  )b k 2i k 2 k 1i i H 2ik 1 2 2 1 01
ip1 k p12
which, in a vectorized form, can be written as
N N0 1
T ˆ ˆS (v) p (1 vS b )S [D  P (S )] .(1)b 2i 2 1i i H 2i1 0
ip1
Interestingly, the score functions (eq. [3]) resemble thoseobtained
from a standard logistic-regression model, except that the design
vector has been replaced by , a quantity incor-T ˆS (1 vS b )S1i 2i 2 1i
porating design variables for both the main and the interaction
effects of .S1
3. Estimate the inverse of the variance-covariance matrix for
, using the formulaS (v)b1
b b 1 11 1I (v) p [I (v) I (v)I I (v)] , (4)b b b w ww wb1 1 1 1
where the expressions for the component informationmatrices—
, and —evalu-T T TI (v) p L/b b I (v) p L/b w I p L/wwb b 1 1 b w 1 ww1 1 1
ated at and are given in the formulae (A2), (A3),ˆb p 0 w p w1
and (A4) (in appendix A). All these quantities can be conveniently
computed using standard logistic-regression software, by simply
setting the design vector for each subject to be X p [1,S ,(12i
.T ˆvS b )S ]2i 2 1i
4. For ﬁxed value of v, obtain the score statistics
T b b1 1T (v) p S (v) I (v)S (v) .1 b b1 1
Compute the ﬁnal test statistics as , where L∗T p max T(v)1 LvU
and U denote some prespeciﬁed values for lower and upper limits
of v, respectively.
Simulating the null distribution of the test statistics.—In appendix
A, we show an asymptotic equivalent representation of the score
statistics as , whereT 1T (v) U (v)V (v)U(v)1
N1
U(v) p U (v) iip1N
denotes the efﬁcient score function for for ﬁxed v (see formulab1
[A5]) and is the limit of . Further, underN TV(v) 1/N U (v)U (v)i iip1
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Figure 4. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.01 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the additive model, with chosen so that∗S G G f1 1 2 2
when and when (see table 2). and denote minor-allele frequencies for causal SNPsMRR p 2.0 f p 0.12 MRR p 5.0 f p 0.04 f f2 2 2 2 1 2
in and , respectively, and denotes the value of multiple between the causal and marker loci within a gene.2 2G G R R1 2 geno
, we show that , as a stochastic process in v, convergesb p 0 U(v)1
to a -variate Gaussian process, , with mean zero and vari-K Z(v)1
ance-covariance function
N
TV(v ,v ) p lim1/N U (v )U (v ) .1 2 i 1 i 2
ip1Nr
We propose to generate realization of the process asZ(v)
N
U (v) p U (v)W ,0 i i
ip1
where and are independent standard normal ran-W i p 1,…,Ni
dom variables that are also independent of the data.30 The null
distribution of the test statistics is then simulated by repeatedlyT1
generating data as , where, in each0 T b ,b T1 1T p max U (v)I (v)U (v)1 LvU 0 0
replication, a new realization of is obtained by regeneratingTU (v)0
the random numbers .(W ,… ,W )1 N
We also considered simulating the null distribution of , using∗T1
a permutation-based resampling method. We randomly per-
muted the value of the vector over different subjectsS i p1i
while holding and to be ﬁxed at their observed1,… ,N N D S0 1 i 2i
values. This yields a valid way of generating null data under the
assumption that and are independent in the underlyingS S1 2
population, because, in this case, the null hypothesis of b p 01
corresponds to independence of and . By permuting allS (D ,S )1i i 2i
the components of simultaneously and keeping ﬁxed,S (D ,S )1i i 2i
the procedure allows within-gene LD patterns and marginal as-
sociation structures of and to be the same as the originalD Gi 2
data.
Design for Simulation Study
We studied performance of the proposed test of association, using
simulated case-control studies. We assumed that the true risk
model involves two potentially interacting causal SNPs, and∗S1
, residing on two separate candidate genes, and , respec-∗S G G2 1 2
tively. For each gene, we assumed that genotype data are available
on six marker SNPs, none of which is the causal SNP. To simulate
a realistic LD pattern among the markers, we used real haplotype
data on glutathione peroxidase 3 (GPX3 [MIM 138321]) and glu-
tathione peroxidase 4 (GPX4 [MIM 138322]), two candidate genes
for prostate cancer that have been resequenced using a sample
of 29 white subjects at the Core Genotyping Facility of the Na-
tional Cancer Institute (NCI). In our simulation, we chose the
marker SNPs for and to correspond to two sets of six taggingG G1 2
SNPs that have been respectively selected for GPX3 and GPX4
with use of the original resequencing data. Table 1 shows the
distribution of the associated haplotypes.
To deﬁne haplotypes for each gene, including the causal locus,
we allowed the major mass of the causal SNP to lie mainly on
one marker haplotype: 001101 for and 010100 or 101100 forG1
, depending on whether a scenario with a common or rareG2
variant, respectively, was considered. We ﬁxed the marginal fre-
quency for a causal SNP to be the same as that for the corre-
sponding main haplotype: 12% for and 12.7% (common) orG1
4.1% (rare) for . To allow for imperfect LD between the causalG2
and the marker SNPs, we allowed for a small amount of recom-
bination between the causal SNP and a set of other marker hap-
lotypes: {000001,000010} for and {100000,101100} or {000010,G1
010010} for , depending on whether a scenario with the com-G2
mon or rare variant was considered.We varied the recombination
fraction (d) at three different values to generate different degrees
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Figure 5. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.01 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the crossover model, with (see table∗S G G f p 0.901 1 2 1
2). and denote minor-allele frequencies for causal SNPs in and , respectively, and denotes the value of multiple between2 2f f G G R R1 2 1 2 geno
the causal and marker loci within a gene.
of LD between the causal and marker SNPs. The values of ,2Rgeno
deﬁned as the squared multiple correlation between the geno-
types at the causal loci and those at the corresponding marker
loci, were 90%, 75%, and 60% in these three settings.
Given the set of haplotype frequencies, in each simulation we
ﬁrst generated diplotype (haplotype-pair) data for a random sam-
ple of subjects, assuming random mating and no LD between
genes. For each subject, we generated a binary disease end point,
or , assuming a general logistic-regression model ofD p 0 D p 1
the formula
∗ ∗ ∗ ∗exp[a v I(S ) v I(S ) v I(S )I(S )]1 1 2 2 12 1 2Pr (D p 1) p ,∗ ∗ ∗ ∗1exp[a v I(S ) v I(S ) v I(S )I(S )]1 1 2 2 12 1 2
(5)
where and are binary indicator variables for the presence∗ ∗I(S ) I(S )1 2
of the variant allele at the respective causal loci. For each given
set of parameter values , , and , the intercept parameter av v v1 2 12
was chosen in such a way that the marginal probability of the
disease in the underlying population is ﬁxed at 1%. In each rep-
lication, we ﬁrst generated data for a large random sample of
subjects, which we then treated as the “study base” to further
select a case-control sample of given size. During analysis of each
set of simulated data, we assumed that genotype data are variable
for the marker SNPs but not for the causal SNPs.
We computed the empirical signiﬁcance level of the proposed
testing procedure, by simulating data under two different settings,
both of which corresponded to the null hypothesis of no asso-
ciation of the disease with . In the ﬁrst setting, we assumed allG1
the association parameters— , , and —to be zero, which im-v v v1 2 12
plied that both and were not associated with the disease.G G1 2
In the second setting, we assumed and to be null but allowedv v1 12
nonzero values for , so that could be associated with thev G2 2
disease even if is not. The signiﬁcance thresholds for the testG1
statistics were obtained using two methods: (1) permutation-∗T1
based resampling of the genotype data of SNPs in and (2) theG1
asymptotic-based method, which requires generation of normal
numbers.
To evaluate power, we simulated data using ﬁve different mod-
els for the joint effect of the two causal SNPs (see table 2). As-
suming rare disease, these settings correspond to (1) the purely
epistatic form, which assumes that the effect of one variant exists
only in the presence of the other and vice versa; (2) the multi-
plicative form, which assumes that the joint effect of the two
variants is given by the product of the main effects of the indi-
vidual variants31; (3) the purely additive form, an approximation
to the genetic heterogeneity model,18 which assumes that the
joint effect of the two variants is given by the sum of main effects
of the individual variants; and (4) the crossover model, which
assumes that the second variant has no effect by itself but that
it reverses the effect of the ﬁrst variant. For eachmodel, we varied
the value of the free risk parameter(s) in a way that the marginal
relative risk (MRR)—the relative risk of the disease associatedwith
one variant when the presence of the other is ignored—associated
with ranges in the set {1.2,1.4,1.6,1.8,2.0}. For the epistatic and∗S1
multiplicative models, the MRR for also varied in the same∗S2
range. For the additive model, we ﬁxed the MRR for to be 2.0∗S2
(low penetrant) and 5.0 (high penetrant) in the common and rare
variant scenarios, respectively. For the crossover model, we as-
sumed (!1), which implies a modest protective effect off p 0.901
in the absence of .∗ ∗S S1 2
We compared power for three different -speciﬁc tests of as-G1
sociation: (1) LogMain, an omnibus 6-df x2 test based on a logistic-
regression model that involves the main effects of only the six
marker SNPs in 12; (2) LogMain&Int, an omnibus 42-df x2 testG1
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Figure 6. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.0001 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the purely epistatic model (see table 2). and∗S G G f1 1 2 1
denote minor-allele frequencies for causal SNPs in and , respectively, and denotes the value of multiple between the2 2f G G R R2 1 2 geno
causal and marker loci within a gene.
based on a logistic-regressionmodel that involves themain effects
of all the SNPs in and and all pairwise interactions betweenG G1 2
SNPs across the two genes (the null model in this test involves
only the main effects of the SNPs in ); and (3) TukAssoc, theG2
proposed test of association based on Tukey’s model of interac-
tion. In each method, the genotype data for the marker SNPs
were coded as continuous variables representing the count for
the respective minor alleles. Asymptotic-based signiﬁcance thresh-
olds were used for all three test statistics. Both type I errors and
powers were obtained empirically, on the basis of 1,000 simulated
data sets.
Results
Simulation Study
Table 3 shows the empirical type I error rates for the pro-
posed testing procedure at a signiﬁcance level of a p
. Both methods performed well in maintaining the0.01
nominal signiﬁcance level in all the different settings
considered.
Figures 2–5 show the empirical power of different pro-
cedures for testing the association of the disease with G1
at a signiﬁcance level of 0.01 under different models for
the joint effects of the underlying causal variants. Similar
examples showing power at a signiﬁcance level of 0.0001
are provided in ﬁgures 6–9.
When the true effects of the causal SNPs were purely
epistatic (ﬁg. 2), the proposed test of association (Tuk-
Assoc), which accounts for interactions, clearly outper-
formed the standard main-effect–based test (LogMain) in
detecting the association of the disease with . GivenG1
the same marginal-effect size for the causal SNP in , theG1
gain in power was larger when the causal SNP in the back-
ground gene, , was rarer, because it corresponded toG2
larger magnitude of the interaction parameter . In thisv12
rare-variant setting, the test based on the saturated model
of interaction (LogMain&Int) also performed better than
themain-effect–based test (LogMain) but lostmajor power
compared with TukAssoc because of the use of large dfs.
As the correlation between the causal and marker SNPs
decreased, the absolute power of all of the different meth-
ods, as expected, decreased. Interestingly, the power of
both interaction-based tests, LogMain&Int and TukAssoc,
relative to LogMain, also decreased as decreased.2Rgeno
When the true effects of the causal SNPs were multi-
plicative (ﬁg. 3), LogMain, which assumes no multiplica-
tive interaction, as expected, had the highest power. The
proposed test, TukAssoc, although not the best, remained
a close second. In contrast, LogMain&Int, which used the
saturated model for interaction, performed very poorly.
When the true model was additive (ﬁg. 4), the power of
TukAssoc remained very close to that of LogMain when
the causal SNP, , in the background gene, , was “com-∗S G2 2
mon low penetrant.” In contrast, under the same model,
when was “rare high penetrant,” TukAssoc showed a∗S2
major gain in power over LogMain. Finally, under the
crossover model (ﬁg. 5), in which the causal variant in
reversed the effect of that in , TukAssoc had muchG G2 1
higher power than LogMain. Often, LogMain&Int also
performed better than LogMain but remained far inferior
to TukAssoc. As observed under the epistatic model, the
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Figure 7. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.0001 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the purely multiplicative model, with∗S G G f p f1 1 2 1 2
(see table 2). and denote minor-allele frequencies for causal SNPs in and , respectively, and denotes the value of multiple2f f G G R1 2 1 2 geno
between the causal and marker loci within a gene.2R
power of both TukAssoc and LogMain&Int relative to Log-
Main decreased for lower values of .2Rgeno
Under each setting described above, the power advan-
tage of TukAssoc compared with the other two procedures
further increased when the signiﬁcance level was chosen
to be 0.0001 instead of 0.01 (see ﬁgs. 6–9).
A Study of NAT2 Acetylation Activity, Smoking, and Risk of
Colorectal Adenoma
Cigarette smoking has been consistently associated with
the risk of colorectal adenoma, a recognized precursor to
colorectal cancer (MIM 114500). Thus, there is interest to
study the risk of adenoma associated with candidate genes
encoding N-acetyltransferase enzymes that are involved
in the metabolism of aromatic amines derived from tobac-
co smoke. N-acetyltransferase 2 (NAT2), located at 8p21.3,
is a candidate gene known to play an important role in
the detoxiﬁcation of certain aromatic carcinogens and,
after N-hydroxylation, in the activation of other amine
protocarcinogens to their ultimate carcinogenic form. We
recently completed a report32 on a case-control study of
the association between NAT2 genetic variants and co-
lorectal adenoma, in relation to tobacco smoking, which
used “case” individuals with left-sided prevalent advanced
adenoma and sex- and age-matched “control” individuals
selected from the screening arm of the large, ongoing Pros-
tate, Lung, Colorectal and Ovarian (PLCO) Cancer Screen-
ing Trial.33,34 The study selected six SNPs (C282T, T341C,
C481T, G590A, A803G, and G857A) for genotyping that
are known to be informative for reconstructing diplotypes
that have been described elsewhere and categorized in lab-
oratory studies as having “slow,” “intermediate,” or “rapid”
N-acetyltransferase enzymatic activity. On the basis of ge-
notype data, 685 cases and 693 controls in the study were
assigned diplotype and related phenotype status with use
of an algorithm developed at the University of Louis-
ville.28,29 The frequency distribution of these diplotypes
and associated phenotypes are shown in table 4. Ques-
tionnaire data on the smoking histories of these subjects
were also available. We categorized subjects, on the basis
of smoking history, as “current,” “former,” or “never.”
Clearly, in the original study,32 the availability of the
prior data to group the numerous diplotypes into a smaller
number of phenotypic categories provided us an oppor-
tunity to investigate the association between NAT2 and
adenoma in a very powerful way. In the current study, we
compared the power of alternative tests that relied on the
original diplotypes themselves, pretending as if the un-
derlying phenotype variable was not observed. It is to be
noted that, for most genomic regions, the phenotypic sig-
niﬁcance of the variants is not well understood and, thus,
the opportunity for grouping the observed genetic vari-
ants into a smaller number of categories may not exist.
Using the diplotype information shown in table 4, we per-
formed three different tests of association between NAT2
and adenoma: (D1) LogMain, an omnibus x2 test based
on a logistic-regression model that involves a main-effect
term for each of the 14 nonreferent diplotypes ( );df p 14
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Figure 8. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.0001 G1
of the underlying causal SNP, . The joint effect of causal SNPs in and follows the additive model, with chosen so that∗S G G f1 1 2 2
when and when (see table 2). and denote minor-allele frequencies for causal SNPsMRR p 2.0 f p 0.12 MRR p 5.0 f p 0.04 f f2 2 2 2 1 2
in and , respectively, and denotes the value of multiple between the causal and marker loci within a gene.2 2G G R R1 2 geno
(D2) LogMain&Int, an omnibus x2 test based on a logistic-
regression model that involves the main effects of the di-
plotypes and all the interactions between the diplotypes
and the two nonreferent categories of smoking; the null
model in this test includes only the main effects of the
smoking categories ( ); and (D3) Tuk-df p 1414#2 p 42
Assoc, an omnibus test of association forNAT2 diplotypes,
based on the model
14 2
log itPr (D p 1) p a b I(H p h ) g I(Smk p k) j j k
jp1 kp1
14 2
v b g I(H p h )I(Smk p k) , j k j
jp1 kp1
where , , and de-I(H p h ) j p 1,…,14 I(Smk p k),k p 1,2j
note the dummy variables for the diplotypes and the
smoking categories. In addition, we also performed two
phenotype-based tests: (P1), a 1-df test for the trend effect
of the phenotype variable that codes it as a continuous
variable—”0” for “slow,” “1” for “intermediate,” and “2”
for “fast”; and (P2), an omnibus test for the main effect
and interactions (with smoking categories) for the contin-
uous phenotype variable ( ). All of the phe-df p 1 2 p 3
notype- and diplotype-based tests were adjusted for age
and sex by including appropriate main-effect terms in
the corresponding logistic-regressionmodel. For computa-
tion of P values, we relied on permutation-based resam-
pling, instead of on the asymptotic-basedmethod,because
of the small number of subjects in some of the diplotype
categories.
From the results shown in table 5, it is clear that, in this
example, the test that captures both the main and the
interaction effects of the phenotype variable was themost
sensitive in detecting the association of adenoma with
NAT2. Among the diplotype-based methods, TukAssoc,
although not signiﬁcant at the traditional 5% level, pro-
vided more evidence of association than the other two
methods considered. This example illustrates two impor-
tant points. First, it shows how incorporating interaction
can improve the power to discover genetic associations.
Second, it shows that the most powerful test for a genetic
association could be obtained when the phenotypic sig-
niﬁcance of the underlying variants are well understood
a priori. If such prior data are not available but the variants
within a genomic region are likely to be functionally re-
lated by a common biological mechanism, such as NAT2
acetylation activity, then the proposed test of association
based on Tukey’s 1-df model of interaction could be a
promising approach.
Discussion
In summary, we have proposed a powerful method for
testing genetic association in case-control studies, by ac-
counting for heterogeneity in disease risk due to gene-gene
and gene-environment interactions. By considering a con-
ceptual framework in which multiple SNPs within a gene
are postulated to be related to a common causal mech-
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Table 4. Distribution of Cases and Controls
by NAT2 Diplotype and Acetylation Phenotype
in the PLCO Adenoma Study
Diplotype
Acetylation
Phenotypea Cases Controls
*5B/*6A 0 155 124
*5B/*5B 0 121 98
*6A/*6A 0 59 73
*5A/*5B 0 16 18
*5B/*7B 0 16 17
*5B/*5C 0 16 10
*6A/*7B 0 10 12
*5A/*6A 0 8 10
*5C/*6A 0 7 9
*4/*5B 1 109 138
*4/*6A 1 86 104
*4/*7B 1 17 8
*4/*5A 1 9 6
*4/*4 2 37 41
Rare … 19 25
a For acetylation phenotype, 0 is slow, 1 is interme-
diate, and 2 is rapid.
Figure 9. Empirical power, at , to detect the association of the disease with candidate gene as a function of the MRRa p 0.0001 G1
of the underlying causal SNP, . The joint effect of casual SNPs in and follows the crossover model, with (see table∗S G G f p 0.901 1 2 1
2). and denote minor-allele frequencies for causal SNPs in and , respectively, and denotes the value of multiple between2 2f f G G R R1 2 1 2 geno
the causal and marker loci within a gene.
anism, we motivate the use of a low-dimensional 1-df
model for gene-gene and gene-environment interactions.
On the basis of thismodel, we have developed an omnibus
gene-speciﬁc test of association that can simultaneously
account for the main effects of the variants within the
region as well as for their interactions with the variants
of another region or with an environmental exposure.We
used both simulated and real data to study the efﬁciency
of the proposed method relative to two standard logistic-
regression–based tests, one ignoring interactions and the
other incorporating a saturated model for interactions.
These studies suggest that the proposed method can im-
prove the power of genetic association tests in the pres-
ence of nonmultiplicative effects of the underlying causal
variants. When the true effects are close to multiplicative,
the proposed method, although it may not be the best,
generally has robust power.
Gene-gene and gene-environment interactions can cause
the effect size of a genetic variant to be heterogeneous for
different subgroups of the population. Tests of genetic as-
sociation that ignore such heterogeneity may lack power,
since the “marginal” effect of a variant when subgroups
are ignored can be quite small, even though its effect can
be quite large in speciﬁc subgroups. Under an extreme
form of interaction in which the effect of a variant may
be in opposite directions in different subgroups, theremay
be no marginal effects even if there are very strong sub-
group effects. Accounting for interaction in association
testing allows one to exploit the full variation in the effects
of the causal variants, at the risk of increasing the number
of parameters to be tested. Our applications involving the
saturated model for interaction suggest that the power
advantage of interaction-based tests may be negated if too
many dfs are spent onmodel for interaction. Theproposed
test based on Tukey’s 1-df model for interaction provides
a good compromise between detecting large genetic effects
versus testing for many parameters.
When multiple SNPs are involved within a gene, one
could attempt to reduce the dfs for related association tests
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Table 5. Test of Association of Adenoma with NAT2, with
and without Accounting for NAT2-Smoking Interaction
Test Test Statistic df P
Acetylation-baseda:
LogMain 3.30 1 .069
LogMain&Int 14.23 3 .003
Diplotype-basedb:
LogMain 18.25 14 .200
LogMain&Int 54.41 42 .156
TukAssoc 26.45 … .071
a Uses continuous phenotype variable codes 0, 1, and 2.
b Uses diplotypes shown in table 4.
on the basis of a derived variable that can combine in-
formation across multiple SNPs by using prior knowledge
about possible directionality of the effects of the variants.35
The acetylation phenotype for the gene used in our data
analysis, NAT2, is a derived variable deﬁned on the basis
of prior data. The scope of such analysis, however, is lim-
ited for contemporary association studies because of the
lack of such prior data on the SNPs. The proposedmethod,
which also uses derived variables—namely, the latent fac-
tors and —does not require any explicit prior dataZ Z1 2
on the directionality of the effects of the SNPs under study.
In particular, the generalized association parameters (b)
allow one to estimate the directionality as well as the
strength of association from the data. Thus, the proposed
method can use a low-df model for interaction without
requiring explicit prior knowledge about the potential ef-
fects of the SNPs.
An alternative approach to reduce the df for association
tests could be to follow a two-stage procedure in which
SNPs are ﬁrst tested for their main effects and, then, in-
teraction-based tests involving only those SNPs for which
main effects were found to be signiﬁcant are considered.
In general, obtaining the correct type I error rates for such
sequential procedures is quite complex. A recent report
suggested a conservative but simple approach for ﬁnding
critical values for SNP-based two-stage tests.36 In a limited
simulation study, we found the power of such a procedure
to be similar to the proposed gene-based one-stage test,
TukAssoc, when each candidate gene under study in-
volved only a single causal variant. In contrast, when the
individual candidate genes involved multiple causal var-
iants, TukAssoc was clearly superior. Further work is needed
to develop more-efﬁcient two-stage tests of association.
Computationally, the proposed score-test statistic is re-
markably simple and can be implemented using standard
logistic-regression software. We have described a simple
and fast way of generating the asymptotic null distribu-
tion of the test statistics. The methodology can be easily
generalized to alternative types of study designs and out-
come traits by simply replacing the logistic model with a
suitable alternative regressionmodel.Moreover, themeth-
ods can be used to test for the collective effect of any group
of functionally related SNPs, which need not be restricted
to candidate genes.
The results from our simulation studies involving two
candidate genes are quite intuitive. When the true effects
of the causal loci across two genes were multiplicative,
tests that were based on the marker SNPs of individual
genes and that ignored gene-gene interactions were op-
timal. This result can be explained mathematically by
the observation that, under the multiplicative model, the
likelihood for case-control data can be factored into two
pieces, each depending on the marker data from a single
gene.20 When the true effects of the causal loci were ad-
ditive—a nonmultiplicative model that is often consid-
ered to be the default for specifying the joint effects of
two exposures acting on nonoverlapping pathways18,37—
the proposed test performed similarly to or substantially
better than the main-effect–based test, depending on the
strength of the main effects of the causal variants. When
the main effects for both causal variants were modest, the
additive model corresponded to only a small departure
from multiplicative effects and, thus, TukAssoc performed
similarly to LogMain. In contrast, when the main effect
of the causal variant in one gene was large, the additive
model corresponded to a large departure from multipli-
cative effects, and TukAssoc became superior. The largest
gains in power for TukAssoc over LogMain were seen for
the epistatic and crossover models, both of which corre-
sponded to a large departure from multiplicative effects.
As expected, the absolute power of all the methods de-
creased as , the correlation between the causal and2Rgeno
the marker SNPs, decreased. Interestingly, the power of
both interaction-based tests, LogMain&Int and TukAssoc,
relative to LogMain also decreased as decreased.When2Rgeno
the markers have low correlation with the respective
causal SNPs, the joint risk of the disease in terms of the
markers may appear close to the multiplicative model
(with nonnull main effects), even if the true effects of the
causal variants are highly epistatic. Thus, for low values
of , models involving only the main effects of the mark-2R
ers may perform well, even if the true effects of the causal
loci are highly interactive. In the context of association
testing using single binary markers, a similar robustness
property for the multiplicative model has been noted
elsewhere.38
In this article, we focused on tests of association for one
candidate gene by exploiting its interaction with another
candidate gene or an environmental exposure. In practice,
however, an association study may involve a variety of
candidate genes and environmental exposures, each of
which may interact with all the others. Clearly, if all the
possible interactions are to be accounted for, the number
of potential tests could be very large. To examine the effect
of the associated multiple-testing problem, we performed
a small simulation study. We used the same setting as
shown in ﬁgure 2 but added eight null genes to the anal-
ysis. Similarly as we did for the two genes that contained
the causal loci, for each of the null genes we assumed that
genotype data are available on six marker SNPs. We used
TukAssoc to assess the signiﬁcance of a speciﬁc gene by
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pairing it with each of the other nine genes and then
taking the maximum of the corresponding nine different
test statistics. To evaluate the critical value of the ﬁnal test
statistic, we used permutation-based resampling that ad-
justs for multiple testing in an efﬁcient way, by taking
into account the correlation among the different test sta-
tistics. Alternatively, we used the standard main-effect–
based test LogMain to test for each gene individually, ig-
noring interactions. For both TukAssoc and LogMain, the
test for each speciﬁc gene was performed at the signiﬁ-
cance level of , to maintain an overall sig-0.01/10p 0.001
niﬁcance level of 0.01. Even with multiple-testing adjust-
ment, TukAssoc remained substantiallymorepowerful than
LogMain in a number of different settings. For example,
in the setting of , , and , the2R p 90 f p 0.13 MRRp 1.62
power for detecting the association of the disease with
was 54% with use of TukAssoc and 34% with use ofG1
LogMain. With and and MRR remaining the2f p 0.04 R2
same as the values above, the power for TukAssoc became
75%, whereas that for LogMain remained at 34%. In the
context of a much-larger-scale study involving a whole-
genome scan, a recent report has made a similar obser-
vation that tests that account for interactions among pairs
of SNPs could be substantially more powerful than those
based only on the main effects of the SNPs, even though
the former class of tests may require a much higher level
of multiple-testing adjustment.36
Nevertheless, we believe that the power advantage of
interaction-based tests would be best realized if the num-
ber of interactions to be considered could be reduced a
priori, on the basis of biological knowledge, previous data,
or/and some prescreening methods. Biological knowledge
of a pathway, for example, may help investigators choose
a few “high-prior” candidate genes that are likely to have
central roles in mediating the biological effects of various
genetic and environmental exposures. In such a setting,
the power of association for the other candidate genes in
that pathway can be improved by accounting for their
interactions with the selected high-prior genes. Data from
previous linkage and association studies could also guide
the selection of such high-prior candidates.
A prescreening method could also reduce the number
of interactions to be tested. For case-control studies involv-
ing candidate SNPs, Millstein et al.25 described a method
that ﬁrst screens for potential interactions by testing for
the signiﬁcance of the correlations among pairs of SNPs
in the pooled case-control sample. If, for a pair of SNPs,
no LD is expected in the population but correlation is
evident in the pooled case-control data, it indicates non-
multiplicative effects of the variants on the risk of the
disease. Moreover, because the screening is done only on
the basis of the genotype data of the subjects, without
regard to their case-control status, subsequent tests of as-
sociation do not require adjustment. Similar ideas can be
adopted to reduce the number of gene-gene interactions
in our setting. For example, one may use a global test of
independence between two sets of SNPs to decide whether
the corresponding gene-gene interaction should be in-
cluded in the subsequent association analysis.
In conclusion, the proposed method, given its efﬁ-
ciency, computational simplicity, and broad applicability,
seems a promising approach for testing genetic association
in the presence of gene-gene and gene-environment in-
teractions. Future work is needed to develop and evaluate
practical strategies for the applications of the methodol-
ogy in large-scale association studies involving speciﬁc
biologic pathways or the whole genome.
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Appendix A
Heuristic Derivation of Tukey’s 1-df Model of
Interaction
Let for , and deﬁne theKjX p m  g S j p 1,2j j k j k jk p1 j jj
function
exp(v  x  x )0 1 2f(x ,x ) p .1 2 1exp(v  x  x )0 1 2
By substituting the regression formula for and (ﬁg.Z Z1 2
1, upper boxes) into the disease-risk model (lower box)
and taking a Taylor’s series expansion, with respect to e1
and , one can writee2
Pr (D p 1FS ,S ) p f(X ,X )1 2 1 2
e ,e1 2
e f (X ,X ) e f (X ,X )1 1 1 2 2 2 1 2
2 2O(e  e ) ,1 1
where , , and de-2 2f (x ,x ) p f(x ,x )/x j p 1,2 O(e  e )j 1 2 1 2 j 1 1
notes a term that can be bounded above by for2 2K(e  e )1 1
a suitable positive constant K. Noting that and aree e1 2
mean zero random variables (conditional on and ),S S1 2
we can write
Pr (D p 1FS ,S ) p E Pr (D p 1FS ,S )1 2 e ,e 1 21 2
e ,e1 2
2 2p f(X ,X )O(j  j ) ,1 2 e e1 2
where denotes the variance of and . Thus, if2j e j p 1,2e jj
and are small, then ,2j j p 1,2 Pr (D p 1FS ,S ) ≈ f(X ,X )e 1 2 1 2j
which is precisely the model shown in equation (1), with
, ,∗ ∗ ∗a p v  v m  v m  v m m b p v g k p 1,…,K ; j p0 1 1 2 2 12 1 2 k j j k j j jj j
, and , where .∗ ∗ ∗1,2 v p v /(v # v ) v p v  v m ,j p 1,212 1 2 j j 12 3j
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Log-Likelihood, Score Function, and Information
Matrices
Let denote , as deﬁned byP (S ,S ) Pr (D p 1FS ,S )a,b ,b ;v 1 2 1 21 2
the proposed model in equation (1). The log-likelihood of
the data under case-control design can be written as
N N1 0
L p D logP (S ,S ) i a,b ,b ;v 1i 2i1 2
ip1
(1D ) log [1P (S ,S )] . (A1)i a,b ,b ;v 1i 2i1 2
Under the null hypothesis that for all , theb p 0 kk 1 11
maximum-likelihood estimates of the parameters w p
, for each ﬁxed value of v, can be obtained by solving(a,b )2
the score equation , whereS (w;v) p 0w
N N0 1
S (w;v) p Z [D  P (S ,S )]w 2i i a,b p0,b ;v 1i 2i1 2
ip1
and . Note that the quantity does notT TZ p (1,S ) P2i 2i a,b ,b ;v1 2
depend on v when , and correspondsb p 0 S (w;v) { S (w)1 w w
to standard logistic-regression score function that involves
only main-effect terms for the marker SNPs in . Let theG2
maximum-likelihood estimates of w under beb p 01
denoted by . Further, let denoteˆ ˆ ˆˆw p (a,b ) P (S ,S )2 NULL 1 2
. Now, for a ﬁxed value of v, the score func-P (S ,S )ˆaˆ,b p0,b ;v 1 21 2
tion for the association parameters and ,b k p 1,…,Kk 1 1 11
evaluated under the null hypothesis that for allb p 0k 11
, can be written in the form of equation (3).k1
Deﬁne to be a design matrix associated withTZ p (1,S )2 2
the standard logistic-regression analysis of the data that
allows for the constant intercept term a and a main-effect
term for each of the markers in . Ignoring terms withG2
expectation zero, the formulae for the information ma-
trices in equation (4), evaluated at and , canˆb p 0 w p w1
be written as
N N0 1
2
Tˆ ˆ[ ]I (v) p 1 vb S P (S ,S ) (A2)b b 2 2i NULL 1i 2i1 1
ip1
T
ˆ#[1P (S ,S )]S S ,NULL 1i 2i 1i 1i
N N0 1
Tˆ ˆ[ ]I (v) p 1 vb S P (S ,S ) (A3)b ,w 2 2i NULL 1i 2i1
ip1
T
ˆ#[1P (S ,S )]S Z ,NULL 1i 2i 1i 2i
and
N N0 1
T
ˆ ˆI p P (S ,S )[1P (S ,S )]Z Z . (A4)w,w NULL 1i 2i NULL 1i 2i 2i 2i
ip1
Efﬁcient Score Function and Asymptotic Theory
Let be the contribution of the i-th subject in theS (v)b ,i1
score vector deﬁned in equation (3). Similarly, letS (v)b1
be the contribution of the i-thˆS p Z [D  P (S ,S i)]w,i 2i i NULL 1i 2
subject to the score vector , evaluated at . De-ˆS (w) w p ww
ﬁne , , and to be the asymptotic limits ofi (v) i (v) ib ,b b ,w w,w1 1 1
the scaled information matrices , , and1 1N I (v) N I (v)b b b w1 1 1
. By using a standard Taylor’s series argument, one1N Iw,w
can represent the score vector in its asymptotic formS (v)b1
N
1/2 1/2N S (v) p N U (v) o (1) ,b i p1
ip1
where denotes the efﬁcient inﬂuence function de-U (v)i
ﬁned by
1U (v) p S (v) i (v)i S (A5)i b ,i b ,w w,w w,i1 1
and represents the term that converges to zero ino (1)p
probability. On the basis of the standard central-limit the-
orem, one can then show that, for any ﬁxed value of v and
under the null hypothesis of , converges1/2b p 0 N S (v)1 b1
to -variate normal distribution with zero mean and var-K1
iance-covariance matrix given by .1 Ti (v) i (v)i i (v)b ,b b ,w w,w b ,w1 1 1 1
Moreover, on any given compact interval for v, the con-V
vergence of the score vector to the correspond-1/2N S (v)b1
ing normal distribution can be shown to be uniform over
v. Thus, it follows that , as a -dimensional1/2N S (v) Kb 11
stochastic process in v, converges to a zero mean Gaussian
process for which the covariance function for the pair
of value is given by the asymptotic limit of(v ,v )1 2
.N1 TN  U (v )U (v )i 1 i 2ip1
Web Resources
The URLs for data presented herein are as follows:
NCI Advanced Technology Center, http://cgf.nci.nih.gov/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for NAT2, GPX3, GPX4, and colorectal
cancer)
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